Erasca, Inc. (ERAS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 5.41B USD. 52-week range 2.10 to 24.28 USD. Data as of 2026-10-09.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of ...